Stockhead on MSN11h
Top of mind: ASX companies tackling neurological disorders
Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders. ...
Investing13d
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment
The company has secured Regenerative Medicine Advanced Therapy (RMAT) designation for Rett syndrome, which could potentially expedite the approval process. An upcoming Type B meeting under the RMAT ...
Business Insider13d
Rett Syndrome Research Trust Appoints Amy Gilliland to its Board of Trustees
Multiple clinical trials in gene therapy for Rett syndrome are now underway, all possible because of RSRT-funded research. In 2024 RSRT launched a $40 million initiative, Roadmap to Cures, with a goal ...
Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc.
Scioto Valley Guardian8d
Cincinnati researchers receive $2 million in grants for groundbreaking Rett Syndrome research
The International Rett Syndrome Foundation (IRSF), headquartered in Cincinnati, has announced the allocation of nearly $2 million in grants to seven leading researchers, ...
Wane21d
Biomed Industries, Inc. Announces Phase 2/3 Results of NA-921, with Superior Efficacy and Safety for Rett Syndrome
Biomed Industries, Inc. Announces Phase 2/3 Results of NA-921, with Strong Efficacy and Superior Safety for Rett Syndrome Treatment The Phase 2/3 results of NA-921 show strong potential as an ...
PharmaTimes13d
Minoryx doses first patient with leriglitazone in Rett syndrome study
Minoryx Therapeutics has dosed the first patient in its phase 2a TREE study, which evaluates the safety and efficacy of ...
Seeking Alpha4d
ACAD ACADIA Pharmaceuticals Inc.
a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to ...